Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven in Infants With Cholestasis
NCT01601652Phase 2Completed
- Start
- Nov 2011
- Primary completion
- Dec 2018
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eicosapentaenoic acid + docosahexaenoic acid in parenteral nutrition-associated cholestasis (PNAC). Primary endpoint: Normalization of Conjugated Bilirubin at 4 months. Started Nov 2011; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
parenteral nutrition-associated cholestasis (PNAC)
Beyond the preview
Go deeper on NCT01601652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01601652.